0.0007USD0.00%Mkt Cap: 88385 USDP/E: 0.00Last update: 2026-05-25
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap88.39K USD
Enterprise Value-381.72K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-18.29M USD
Revenue/Share—
Last Price0.0007 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.00
P/E (Forward)-0.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)2.44
EPS (Forward)-1.09
52W Range
0.00013% of range0.0200
52W High0.0200 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-540.31%
ROA-321.98%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.77M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3418.01%
Net Debt-444.86K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.36
Quick Ratio0.20
Book Value/Sh-0.1780 USD
Cash/Share0.0040 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:17
Split DateOct 31, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.126.26M
Float—
Insiders0.00%
Institutions0.15%
Short Interest
Short Ratio0.1d
Short % Float8.62%
Short % Out.8.54%
Shares Short637.72K
Short (prev mo.)552.33K
Technical
SMA 500.0005 (+29.6%)
SMA 2000.0004 (+60.2%)
Beta-33.68
S&P 52W Chg28.31%
Avg Vol (30d)1.98K
Avg Vol (10d)2.64K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—